SHARE

As per the report published by Fior Markets, the global antibiotics market is expected to grow from USD 46.71 Billion in 2018 to USD 67.25 Billion by 2026 at a CAGR of 4.7% during the forecast period 2019-2026.North America region is dominating the market owing to an increased use of antibiotics. In addition, there is a rise in per capita health expenditure in the country, which is expected to increase over the forecast period, due to decrease in the unemployment rate.

Antibiotics Market by Action (Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, Others),Drug Class,Spectrum of Activity, Route of Administration, Region, Global Industry Analysis, Market Size, Share, Growth, Trends, and Forecast 2019 to 2026.

DOWNLOAD FREE SAMPLE REPORT AT:https://www.fiormarkets.com/report-detail/396103/request-sample

Leadersin the industry such as Pfizer, Inc; Janssen Pharmaceuticals; Abbott laboratories; GlaxoSmithKline plc; Sanofi S.A.; Novartis AG; Bayer AG; Bristol Myers Squibb Company; Eli Lilly & Company, and Astellas Pharma, Inc, Allergan Plc, F.Hoffmann-La Roche Ltd, Merck & Co. Inc., Mylan N.V., Sanofi, Teva Pharmaceutical Industries Ltd,Aurobindo Pharma, Lupin Pharmaceuticals, Sun Pharmaceutical, Shionogi, among others. In order to enhance the market position, key players are now focusing on adopting strategies such as product innovations, mergers & acquisitions, recent developments, joint venture, collaborations, and partnership. For instance, In August 2016, Pfizer entered into an agreement with AstraZeneca to acquire the development and commercialization rights to its late-stage small molecule anti-infective business, mainly outside U.S.

Antibiotics are also known as antibacterial or antimicrobials. It is defined as a group of medicines used in the treatment of infections caused by germs-bacteria and certain parasites by inhibiting the growth of microorganisms or killing them.The antibiotics market is segmented on the basis of action, drug class, spectrum of activity, and route of administration.The action segment is segmented into cell wall synthesis inhibitors, protein synthesis inhibitors, DNA synthesis inhibitors, RNA synthesis inhibitors and mycolic acid inhibitors. RNA synthesis inhibitors segment is growing with the highest CAGR of 6.1% in the forecast period. Adoption of several antiviral drugs inhibiting transcription and reverse transcription process are expected to promote the growth of the market. The drug class segment is segmented into cephalosporin, penicillin, fluoroquinolone, macrolides, carbapenem, aminoglycosides, sulfonamides and other. The other antibiotics segment is anticipated to expand at the highest CAGR of 7.6% during the forecast year. The other antibiotics segment comprises of tetracyclines, imidazoles, lincosamides, and monoclonal antibodies. The development of monoclonal antibodies for individuals that have developed antibiotic-resistance is a vital component for the growth of this segment.The spectrum of activitysegment is segmented into broad-spectrum antibiotic and narrow-spectrum antibiotic. The broad-spectrum antibiotic segment is dominating the market with the highest share of 59.90% in 2018. Broad-spectrum antibiotics act against a wide range of diseases, which in turn helps to combat antimicrobial resistance.The route of administration segment is segmented into oral, intravenous and others. The intravenous segment is dominating the market and valued around USD23.77 Billion in 2018 due to rise in incidence of severe infections. Moreover, as intravenous antibiotics are administered in higher concentrations, they reach in the tissues faster as compared to oral antibiotics.

Access full report with TOC at:https://www.fiormarkets.com/report/antibiotics-market-by-action-cell-wall-synthesis-inhibitors-396103.html

Development of better and improved products has stimulated the growth. Rising incidences of infectious diseases is another factor contributing to the market expansion. Also, increasing collaborative development effortsis also propelling the growth of the market. Butuncertain regulatosry policies may pose a major threat to the product. However, evolution of advanced molecules and novel combination therapies to treat antibiotic-resistant microbial infections is likely to spur market growthin coming years.

Customization of the Report:This report can be customized to meet the client’s requirements. Please connect with our sales team (sales@fiormarkets.com), who will ensure that you get a report that suits your needs.